Riluzole as a neuroprotective drug for spinal cord injury: From bench to bedside

Narihito Nagoshi, Hiroaki Nakashima, Michael G. Fehlings

Research output: Contribution to journalReview article

34 Citations (Scopus)

Abstract

Spinal cord injury (SCI) is a devastating event resulting in permanent loss of neurological function. To date, effective therapies for SCI have not been established. With recent progress in neurobiology, however, there is hope that drug administration could improve outcomes after SCI. Riluzole is a benzothiazole anticonvulsant with neuroprotective effects. It has been approved by the U.S. Food and Drug Administration as a safe and well-tolerated treatment for patients with amyotrophic lateral sclerosis. The mechanism of action of riluzole involves the inhibition of pathologic glutamatergic transmission in synapses of neurons via sodium channel blockade. There is convincing evidence that riluzole diminishes neurological tissue destruction and promotes functional recovery in animal SCI models. Based on these results, a phase I/IIa clinical trial with riluzole was conducted for patients with SCI between 2010 and 2011. This trial demonstrated significant improvement in neurological outcomes and showed it to be a safe drug with no serious adverse effects. Currently, an international, multi-center clinical trial (Riluzole in Acute Spinal Cord Injury Study: RISCIS) in phase II/III is in progress with riluzole for patients with SCI (clinicaltrials.gov, registration number NCT01597518). This article reviews the pharmacology and neuroprotective mechanisms of riluzole, and focuses on existing preclinical evidence, and emerging clinical data in the treatment of SCI.

Original languageEnglish
Pages (from-to)7775-7789
Number of pages15
JournalMolecules
Volume20
Issue number5
DOIs
Publication statusPublished - 2015 May 1

Fingerprint

spinal cord injuries
Riluzole
Neuroprotective Agents
Spinal Cord Injuries
seats
drugs
anticonvulsants
pharmacology
synapses
Clinical Trials, Phase I
Neurobiology
Sodium Channels
Amyotrophic Lateral Sclerosis
United States Food and Drug Administration
neurons
Pharmaceutical Preparations
Anticonvulsants
Synapses
Neurons
destruction

Keywords

  • Clinical trial
  • Neuroprotection
  • Riluzole
  • Spinal cord injury

ASJC Scopus subject areas

  • Medicine(all)
  • Organic Chemistry

Cite this

Riluzole as a neuroprotective drug for spinal cord injury : From bench to bedside. / Nagoshi, Narihito; Nakashima, Hiroaki; Fehlings, Michael G.

In: Molecules, Vol. 20, No. 5, 01.05.2015, p. 7775-7789.

Research output: Contribution to journalReview article

Nagoshi, Narihito ; Nakashima, Hiroaki ; Fehlings, Michael G. / Riluzole as a neuroprotective drug for spinal cord injury : From bench to bedside. In: Molecules. 2015 ; Vol. 20, No. 5. pp. 7775-7789.
@article{a4155b188858496791bc9e91417ca8e6,
title = "Riluzole as a neuroprotective drug for spinal cord injury: From bench to bedside",
abstract = "Spinal cord injury (SCI) is a devastating event resulting in permanent loss of neurological function. To date, effective therapies for SCI have not been established. With recent progress in neurobiology, however, there is hope that drug administration could improve outcomes after SCI. Riluzole is a benzothiazole anticonvulsant with neuroprotective effects. It has been approved by the U.S. Food and Drug Administration as a safe and well-tolerated treatment for patients with amyotrophic lateral sclerosis. The mechanism of action of riluzole involves the inhibition of pathologic glutamatergic transmission in synapses of neurons via sodium channel blockade. There is convincing evidence that riluzole diminishes neurological tissue destruction and promotes functional recovery in animal SCI models. Based on these results, a phase I/IIa clinical trial with riluzole was conducted for patients with SCI between 2010 and 2011. This trial demonstrated significant improvement in neurological outcomes and showed it to be a safe drug with no serious adverse effects. Currently, an international, multi-center clinical trial (Riluzole in Acute Spinal Cord Injury Study: RISCIS) in phase II/III is in progress with riluzole for patients with SCI (clinicaltrials.gov, registration number NCT01597518). This article reviews the pharmacology and neuroprotective mechanisms of riluzole, and focuses on existing preclinical evidence, and emerging clinical data in the treatment of SCI.",
keywords = "Clinical trial, Neuroprotection, Riluzole, Spinal cord injury",
author = "Narihito Nagoshi and Hiroaki Nakashima and Fehlings, {Michael G.}",
year = "2015",
month = "5",
day = "1",
doi = "10.3390/molecules20057775",
language = "English",
volume = "20",
pages = "7775--7789",
journal = "Molecules",
issn = "1420-3049",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "5",

}

TY - JOUR

T1 - Riluzole as a neuroprotective drug for spinal cord injury

T2 - From bench to bedside

AU - Nagoshi, Narihito

AU - Nakashima, Hiroaki

AU - Fehlings, Michael G.

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Spinal cord injury (SCI) is a devastating event resulting in permanent loss of neurological function. To date, effective therapies for SCI have not been established. With recent progress in neurobiology, however, there is hope that drug administration could improve outcomes after SCI. Riluzole is a benzothiazole anticonvulsant with neuroprotective effects. It has been approved by the U.S. Food and Drug Administration as a safe and well-tolerated treatment for patients with amyotrophic lateral sclerosis. The mechanism of action of riluzole involves the inhibition of pathologic glutamatergic transmission in synapses of neurons via sodium channel blockade. There is convincing evidence that riluzole diminishes neurological tissue destruction and promotes functional recovery in animal SCI models. Based on these results, a phase I/IIa clinical trial with riluzole was conducted for patients with SCI between 2010 and 2011. This trial demonstrated significant improvement in neurological outcomes and showed it to be a safe drug with no serious adverse effects. Currently, an international, multi-center clinical trial (Riluzole in Acute Spinal Cord Injury Study: RISCIS) in phase II/III is in progress with riluzole for patients with SCI (clinicaltrials.gov, registration number NCT01597518). This article reviews the pharmacology and neuroprotective mechanisms of riluzole, and focuses on existing preclinical evidence, and emerging clinical data in the treatment of SCI.

AB - Spinal cord injury (SCI) is a devastating event resulting in permanent loss of neurological function. To date, effective therapies for SCI have not been established. With recent progress in neurobiology, however, there is hope that drug administration could improve outcomes after SCI. Riluzole is a benzothiazole anticonvulsant with neuroprotective effects. It has been approved by the U.S. Food and Drug Administration as a safe and well-tolerated treatment for patients with amyotrophic lateral sclerosis. The mechanism of action of riluzole involves the inhibition of pathologic glutamatergic transmission in synapses of neurons via sodium channel blockade. There is convincing evidence that riluzole diminishes neurological tissue destruction and promotes functional recovery in animal SCI models. Based on these results, a phase I/IIa clinical trial with riluzole was conducted for patients with SCI between 2010 and 2011. This trial demonstrated significant improvement in neurological outcomes and showed it to be a safe drug with no serious adverse effects. Currently, an international, multi-center clinical trial (Riluzole in Acute Spinal Cord Injury Study: RISCIS) in phase II/III is in progress with riluzole for patients with SCI (clinicaltrials.gov, registration number NCT01597518). This article reviews the pharmacology and neuroprotective mechanisms of riluzole, and focuses on existing preclinical evidence, and emerging clinical data in the treatment of SCI.

KW - Clinical trial

KW - Neuroprotection

KW - Riluzole

KW - Spinal cord injury

UR - http://www.scopus.com/inward/record.url?scp=84929208524&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929208524&partnerID=8YFLogxK

U2 - 10.3390/molecules20057775

DO - 10.3390/molecules20057775

M3 - Review article

C2 - 25939067

AN - SCOPUS:84929208524

VL - 20

SP - 7775

EP - 7789

JO - Molecules

JF - Molecules

SN - 1420-3049

IS - 5

ER -